Puyuan Y. Xing

Chinese Academy Of Medical Science And Peking Union Medical College
Beijing, 100021, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 146 publications

First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.

First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 20, 2026

Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.

Biomarker exploration for immunotherapy plus chemotherapy following resistance to third-generation EGFR-TKIs in lung adenocarcinoma.

Journal: BMC cancer
Published: February 18, 2026

Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.

Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.

Journal: Signal transduction and targeted therapy
Published: October 18, 2025

Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Journal: Translational lung cancer research
Published: October 09, 2025

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Journal: Thoracic cancer
Published: August 30, 2025

DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 31, 2025

Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients.

Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients.

Journal: Frontiers in microbiology
Published: July 21, 2025

DNAJA: emerging targets for anti-tumor therapy.

DNAJA: emerging targets for anti-tumor therapy.

Journal: Future oncology (London, England)
Published: June 03, 2025

First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes.

First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes.

Journal: Thoracic cancer
Published: April 07, 2025

A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

Journal: Thoracic cancer
Published: March 24, 2025

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Journal: Signal transduction and targeted therapy
Published: March 20, 2025

Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer.

Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer.

Journal: Translational lung cancer research
Published: February 26, 2025
Showing 1-12 of 146

Last Updated: 09/26/2026